New Two-Drug attack on tough cancers shows early promise
NCT ID NCT05293496
Summary
This early-stage study tested the safety of combining two experimental drugs, vobramitamab duocarmazine and lorigerlimab, in people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find a safe dose and see how the body processes the drugs, while also looking for early signs that the combination could shrink tumors. The study included 31 people with cancers like advanced prostate cancer, melanoma, and pancreatic cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Carolina BioOncology
Huntersville, North Carolina, 28078, United States
-
Florida Cancer Specialists and Research Institute
Sarasota, Florida, 34232, United States
-
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, 21287, United States
-
Stephenson Cancer Center, The University of Oklahoma
Oklahoma City, Oklahoma, 73104, United States
-
University of California, Los Angeles
Los Angeles, California, 90095, United States
-
University of California, San Francisco
San Francisco, California, 94115, United States
-
University of Pittsburgh Medical Center, Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
-
University of Virginia Comprehensive Cancer Center
Charlottesville, Virginia, 22908, United States
-
Weill Cornell Medicine
New York, New York, 10065, United States
-
Winship Cancer Institute of Emory University
Atlanta, Georgia, 30322, United States
Conditions
Explore the condition pages connected to this study.